Hospital Pharmacy Segment to Dominate India Anti-Fungal Drugs Market through FY2027
Supportive government policies and rise of disposable income is expected to drive the demand for India anti-fungal drugs market for the forecast period.
According to TechSci Research report, “India Anti-Fungal Drugs Market By Drug Class (Azoles, Echinocandins, Polyenes, Allylamines, Others) By Indication (Mucormycosis, Dermatophytosis, Aspergillosis, Candidiasis, Others (Cryptococcosis, Coccidioidomycosis) By Infection Type (Superficial Fungal Infection, Systemic Fungal Infection) By Route of Administration (Oral, Topical, Parenteral, Others) By End-User (Hospitals, Homecare, Specialty Clinics, Others) By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) By Company, By Region, Forecast & Opportunities, FY2027”, The India anti-fungal drugs market is expected to witness steady growth for the next five years. Fungi are defined as microorganisms which can cause variety of infections such as growth of the superficial itchy skin upon contact with human body. These kind of infections takes place due to the presence of low immune systems or exposure to unhygienic environment containing fungus to the human body. Fungal infections generally occur on skin, hair and lungs and affects the body adversely. Anti-fungal drugs are used for treatment of these infections. These anti-fungal drugs can be easily obtained either through over the counter or through doctor’s prescription. Surge in number of infectious diseases due to presence of unhygienic conditions in rural areas is accelerating the demand for anti-fungal drugs in India. Treatment in healthcare facilities can lead to hospital-acquired diseases such as nosocomial infections. Also, the other responsible for nosocomial infections are increasing prevalence of cancer and other diseases which lowers the immune system of patients.
The COVID-19 outbreak across the world which has been declared as pandemic by World Health Organization has affected countries adversely. Leading authorities of India imposed lockdown restrictions and released a set of precautionary measures to contain the spread of novel coronavirus. Coronavirus affected patients started suffering from shortness of breath along with coughing and sneezing. India authorities increased the capacity of hospitals as a greater number of patients were getting affected daily and getting admitted into the hospital facilities. Patients suffering from COVID-19 found to have small amounts of Interferon’s in lungs or blood. Anti-fungal drugs along with anti-depressant drugs are used widely for treatment of patients which is expected to positively influence the market growth.
However, stringent government regulations for approval of drugs and long-term usage of drugs along with rising side-effects may hamper the anti-fungal market growth for the forecast period.
Browse XX Figures spread through XX Pages and an in-depth TOC on “India Anti-Fungal Drugs Market”.
https://www.techsciresearch.com/report/india-anti-fungal-drugs-market/7491.html
India anti-fungal drugs market is segmented into drug class, indication, infection type, route of administration, end-user, distribution channel, regional distribution, and company. Based on indication, market is further divided into mucormycosis, dermatophytosis, aspergillosis, candidiasis, and others. The dermatophytosis segment is expected to dominate the market for the forecast period, FY2023-FY2027. Increase in occurrence of dermatophytosis across India and presence of unhygienic environmental conditions is fueling the growth of the anti-fungal drugs market growth. Based on route of administration, anti-fungal drugs market is majorly classified into oral, topical, parenteral and others. The topical segment is anticipated to witness significant growth during the forecast period. Use of topical drugs for treatment of dermatological fungal infections is a major driver for the anti-fungal drugs market. Higher concentration of drugs can be applied to affected area and small number of doses is required for topical drug delivery. Based on distribution channel, market is fragmented into hospital pharmacy, online pharmacy, and retail pharmacy. The hospital pharmacy segment is expected to hold lion’s share for the next five years as large number of patients visit every day for treatment of various diseases. Increase in awareness regarding health and its benefits is also expected to boost the anti-fungal drugs market growth.
Pfizer India Ltd., Cipla Ltd., Glenmark Pharmaceuticals Ltd., Sun Pharmaceuticals Industries Ltd., Dr. Reddy’s Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Lupin Ltd., Zydus Cadila Ltd., Novartis India Ltd., Torrent Pharmaceuticals Ltd. are the leading players operating in India anti-fungal drugs market. Manufacturers are increasingly focusing on research and development process to fuel higher growth in the market. To meet evolving customer demand with respect to better efficiency and durability, several anti-fungal drugs manufacturers are coming up with their technologically advanced offerings.
Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=7491
Customers can also request for 10% free customization on this report.
“Manufacturers are heavily investing to formulate advanced medication techniques for efficient treatment of anti-fungal diseases. Rise in use of nanotechnology for delivering medicines with better outcomes such as treatment of nail fungus and launch of nanostructured drug delivery systems for treatment of vaginal and oral candidiasis is expected to accelerate the demand for anti-fungal drugs. Government support for production of anti-fungal on a large scale for treatment of patients suffering from coronavirus is expected to propel the growth of the anti-fungal drugs market until FY2027” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based global management consulting firm.
“India Anti-Fungal Drugs Market By Drug Class (Azoles, Echinocandins, Polyenes, Allylamines, Others) By Indication (Mucormycosis, Dermatophytosis, Aspergillosis, Candidiasis, Others (Cryptococcosis, Coccidioidomycosis) By Infection Type (Superficial Fungal Infection, Systemic Fungal Infection) By Route of Administration (Oral, Topical, Parenteral, Others) By End-User (Hospitals, Homecare, Specialty Clinics, Others) By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) By Company, By Region, Forecast & Opportunities, FY2027” has evaluated the future growth potential of India anti-fungal drugs market and provided statistics & information on market size, shares, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in the of India anti-fungal drugs market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com/
